SCHEDULE: Affinity Asset Advisors Reports 5.6% Stake in Forte Biosciences

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,145,391 shares, representing 5.6% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Affinity Asset Advisors, LLC, acting as the investment manager for Affinity Healthcare Fund, LP, and its managing member Michael Cho, have disclosed their beneficial ownership of Forte Biosciences, Inc. common stock.
• As of June 30, 2026, the total beneficial ownership is 1,145,391 shares.
• This holding represents approximately 5.6% of the outstanding common stock.
• The filing is an amendment (Amendment No. 3) to a Schedule 13G.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.

Positives

• The filing clearly states the beneficial ownership percentage, providing transparency to the market.
• The reporting persons affirm that their holdings are for ordinary course of business purposes, suggesting no immediate intent to disrupt company control.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Forte Biosciences, Inc.

Risks

• While not explicitly stated as a risk in this filing, significant ownership by an investment advisor could lead to future activism or changes in strategic direction if the advisor's investment thesis evolves.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in this Schedule 13G, is common in the biotechnology sector. Such filings provide transparency regarding major shareholders who may influence corporate strategy or governance.

Stakeholder Impact

• Shareholders gain clarity on a significant beneficial owner, potentially influencing market perception.
• Management of Forte Biosciences, Inc. is aware of the reporting persons' stake and their stated intent to hold shares in the ordinary course of business.

Next Steps

• Affinity Asset Advisors, LLC and Michael Cho will continue to manage their investment in Forte Biosciences, Inc. according to their investment strategy.
• Forte Biosciences, Inc. will continue its operations as disclosed in its previous filings.

Key Dates

Keywords

Forte Biosciences, Affinity Asset Advisors, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Affinity Healthcare Fund